United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

29 Jul 2016
Change (% chg)

€0.20 (+0.60%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Carmat obtains necessary approvals to begin PIVOTAL study in France
Wednesday, 13 Jul 2016 02:07am EDT 

Carmat SA : Carmat has obtained the necessary approvals to begin the PIVOTAL study in France .Simultaneously, Carmat has begun procedures to obtain approval to implant its artificial heart in other European countries.  Full Article

Carmat begins CE Certification process for its artificial heart
Thursday, 23 Jun 2016 12:00pm EDT 

Carmat SA : Carmat has begun, with Dekra, the ce certification process for its bioprosthetic artificial heart .Assessment aims to ensure its compliance with European regulatory requirements.  Full Article

Carmat completes its EUR 50.0 mln reserved capital increase
Wednesday, 27 Apr 2016 02:08am EDT 

Carmat SA:Carmat completes its 50.0 million euros reserved capital increase.1,349,159 new shares issued should be listed on Alternext Paris market from April 28.  Full Article

Carmat announces 50 mln euro equity financing
Friday, 26 Feb 2016 08:37am EST 

Carmat SA:Announces capital increase plan for minimum of 50.0 million euros.Pool of strategic investors will fully subscribe 50.0 million euro equity financing.Airbus is taking 22.0 pct; Cornovum (Bpifrance & french state) is taking 34.0 pct.  Full Article

Carmat updates on feasibility study of bioprosthetic artificial heart
Tuesday, 22 Dec 2015 12:38pm EST 

Carmat SA:Says ‍third patient, who was implanted with a Carmat prosthesis on April 8, died on morning of Dec. 18.Says ‍analyses carried out do not show that prosthesis was involved in patient's death.Says is continuing feasibility study.  Full Article

Carmat SA announces appointment of CFO
Tuesday, 26 May 2015 11:45am EDT 

Carmat SA:Appoints Benoît de la Motte as CFO.  Full Article

Carmat announces initial details of analysis of CARMAT Heart implanted in second patient
Tuesday, 5 May 2015 02:30pm EDT 

Carmat SA:Presents first elements of analysis of CARMAT bioprosthesis implanted in second patient.Patient lived virtually normal life with CARMAT prosthesis for nine months.Initial analysis following this relatively long period shows the prosthesis' biocompatibility with organism and blood.Design's fundamentals have thus been corroborated.  Full Article

Carmat Heart implanted in a third patient
Tuesday, 28 Apr 2015 12:00pm EDT 

Carmat SA:Confirms implantation of the CARMAT heart in a third patient at the Georges Pompidou European Hospital.This third implantation of CARMAT heart was carried out on April 8 by Georges Pompidou European Hospital team and went smoothly.  Full Article

Carmat SA to sell up to 50 millions euros worth of shares
Sunday, 25 Jan 2015 07:00pm EST 

Carmat SA:Plans to sell up to 50 million euros ($56 million) of shares in three blocs to help it finance ongoing clinical trials of its artificial heart.Says Bank Kepler Cheuvreux will provide the financing via a so-called contingent equity line, which consists of an immediate first tranche of 20 million euros and a further two optional chunks of 15 million euros each.Says the issue price of the shares will depend on Carmat's prevailing share price, discounted by no more than 6 percent.Says Kepler Cheuvreux will subscribe to a total of 20 million euros of shares in the next 12 months.Says some 303,865 new Carmat SA shares will be issued, or about 6.5 percent of the company's share capital.  Full Article

BRIEF-Carmat obtains necessary approvals to begin PIVOTAL study in France

* Carmat has obtained the necessary approvals to begin the PIVOTAL study in France